Sign in
Taking people in United StatesPhase 2

Tests dronabinol for pain and inflammation in sickle cell disease

Tests dronabinol against placebo for pain in adults with sickle cell disease.

Key facts

Who runs it
Icahn School of Medicine at Mount Sinai
Where
New York, United StatesSee the site
Trial code
Registry title
Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
Status
Recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
3 Apr 2025
Expected to end
1 May 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Dronabinol
  • Placebo
Record updated
2 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with sickle cell disease who have chronic pain. It tests dronabinol against a placebo for pain and inflammation.

Age
Over 18 years
Sex
All sexes can join.
Disease stage
Clinical diagnosis of sickle cell disease (HbSS, HbSC, HbSβ+ thalassemia, HbSβ0 thalassemia or HbS variants). Baseline score of 60 or lower on the ASCQ-Me 7-day pain interference domain.
Earlier treatment
If on a sickle cell disease modifying therapy (hydroxyurea, regular blood transfusions, L-glutamine, voxelotor, crizanlizumab), the dose must be stable for at least 3 months. If using opioids for pain at home, the dose must be stable for at least 3 months.
Biomarker or test result
One urine test negative for cannabinoids within 30 days of randomization.

Main reasons for not taking part

  • Pregnant or nursing
  • Daily cannabis use
  • Active substance use disorder
  • History of psychotic episode, psychosis, or active suicidality
  • Known intolerance to dronabinol or marijuana

The registry criteria, word for word

Show all 15 criteriaShow less

Other criteria

  • Age >18 years
  • Clinical diagnosis of SCD (HbSS, HbSC, HbSβ+; Thal, HbSβ0Thal, HbS variants)
  • Baseline score of 60 or lower on the ASCQ-Me 7-day pain interference domain
  • If on a SCD modifying therapy (hydroxyurea, regular blood transfusions, L-glutamine, voxelotor, crizanlizumab), on stable dose for at least 3 months
  • If using opioids for pain at home, on stable dose for at least 3 months
  • One urine toxicology negative for cannabinoids within 30 days of randomization
  • No known intolerance to dronabinol, or marijuana
  • No history of psychotic episode, psychosis, or active suicidality
  • No contraindication to dronabinol with attention to potential side effects, concurrent medications/substances, and concurrent medical problems, as evaluated by a physician
  • Willing to abstain from cannabis, medical and illicit, during study weeks 1 through 8
  • Not pregnant or nursing
  • If a woman capable of becoming pregnant, willing to use a medically accepted form of birth control for the duration of study participation. Accepted forms include oral contraception, medroxyprogesterone, contraceptive implants or patch, surgical sterilization, total abstinence
  • Able to consent for research
  • No daily cannabis use
  • No diagnosis of active substance use disorder

Where in United States

  • Mount Sinai HospitalNew York, United StatesContact: Susanna Curtis, MD, PhDTaking people

About the trial

What the trial wants to find out

A randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).

The 2 groups in the trial

  • DronabinolTreatment being tested

    BID for 8 weeks. Dosage will be individualized per patient. In days 1-4 of the study each patient will be titrated from 5mg bid to a minimum dose of 2.5 mg bid to a maximum dose of 10 mg bid depending on patient preference.

  • PlaceboPlacebo, for comparison

    A placebo comparator

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Dronabinol for the Reduction of Chronic Pain and Inflammation in People With Sickle Cell Disease
Plain-language title
Tests dronabinol for pain and inflammation in sickle cell diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 October 2025